WALTHAM, Mass., Dec. 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, according to responses from surveyed dermatologists, Centocor Ortho Biotech/Janssen-Cilag's Stelara and Abbott's briakinumab (both interleukin inhibitors) will capture 22 percent of the biologics share in 2012 in the drug market for moderate to severe psoriasis. Among these two agents, Stelara will experience greater uptake, capturing nearly three times as much patient share as briakinumab.
The new Physician & Payer Forum report entitled The Next Wave of Psoriasis Biologics: Physician and Payer Perspectives on Novel Interleukin Inhibitors finds that, among the currently-available TNF-alpha inhibitors, Amgen/Pfizer/Takeda's Enbrel--the most-prescribed biologic in psoriasis--will lose the greatest percentage of sales as a result of Stelara's uptake. By the end of 2012, surveyed physicians expect to use Stelara in 16 percent of biologics-treated patients with moderate to severe psoriasis. Additionally, Abbott/Eisai's TNF-alpha inhibitor Humira will also lose substantial market share to Stelara. However, the report finds that other biologics such as Centocor Ortho Biotech/Merck/Mitsubishi Tanabe's Remicade (a TNF-alpha inhibitor) and Astellas's Amevive (a T-cell modulator) are expected to preserve their limited market share, owing to their status as niche therapies.
"Currently, biologic treatment for psoriasis is overwhelmingly dominated by Enbrel, Humira and Remicade as these agents have proved effective and, after years of marketing, physicians' concerns about the long-term safety of these drugs have eased somewhat," said Decision Resources Analyst Joanna Kim, M.Ed. "However, the landscape for biologic therapies in psoriasis experienced a noteworthy shift when Genentech/Merck Serono's T-cell modulator Raptiva was withdrawn from the market earlier this year owing to serious safety concerns."
The report also finds that, when asked about the likelihood of coverage for Stelara and briakinumab if both agents are priced equally, more surveyed managed care organizations' (MCOs) pharmacy directors indicate that they would reimburse Stelara than briakinumab. Among surveyed pharmacy directors who expect to cover both agents in their formularies; three-quarters say they will place Stelara on the same tier as currently-available TNF-alpha inhibitors or on a more favorable tier while two-thirds will do so for briakinumab. Their reasons for positioning Stelara at a small advantage over briakinumab relate to long-term safety data and clinical advantage over other agents.
The Next Wave of Psoriasis Biologics: Physician and Payer Perspectives on Novel Interleukin Inhibitors is based on a U.S. survey of 102 dermatologists and 21 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Decision Resources Decision Resources, Inc. Christopher Comfort Elizabeth Marshall 781-296-2597 781-296-2563 email@example.com firstname.lastname@example.org
SOURCE Decision Resources
|SOURCE Decision Resources|
Copyright©2009 PR Newswire.
All rights reserved